No Data
No Data
Noile-Immune Biotech: Notice regarding publication of earnings forecasts
Noile-Immune Biotech: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Asahi, Matsukiyo, Dentsu Group, Lancers (14th) (1379-4990)
※The above calendar is merely a schedule and may be subject to change due to the company's circumstances. --------------------------------------- November 14 (Thursday) <1379> Hokuto <1380> Akikawa Bokuen <142A> Jinjibu <1438> Gifu Landscape <1443> Giken HD <1446> Candiule <1447> SAAF HD <145A> El
Noile-Immune Biotech: Correction Confirmation Form
Noile-Immune Biotech: Revised Semi-Annual Report - Term 10 (2024/01/01 to 2024/12/31)
Emerging markets outlook: Interested in confirming the increase in trading volume in growth markets.
Interest in leading stocks did not increase, and the trading volume stunk this week in the emerging markets. During the same period, while the Nikkei average fell by -3.00%, the growth market index fell by -3.69%, and the growth market 250 index fell by -4.22%. Similar to the prime market, there was a rollback of 'high market trades' at the beginning of the week, causing a decline. Subsequently, the situation was swayed by the words and actions of the new Prime Minister Ishiba, leading to caution in buying leading stocks and short-term funds flowing into recent IPO stocks. Reasons such as the lack of increasing interest in leading stocks.
No Data
No Data